Canlyniadau Chwilio - McMeekin, D Scott

Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents gan Moxley, Katherine M., McMeekin, D. Scott

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P gan Dizon, Don S., Blessing, John A., McMeekin, D. Scott, Sharma, Sudarshan K., DiSilvestro, Paul, Alvarez, Ronald D.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A PHASE II TRIAL OF THALIDOMIDE IN PATIENTS WITH REFRACTORY ENDOMETRIAL CANCER AND CORRELATION WITH ANGIOGENESIS BIOMARKERS: A GYNECOLOGIC ONCOLOGY GROUP STUDY gan McMeekin, D. Scott, Sill, Michael W., Benbrook, Doris, Darcy, Kathleen M., Stearns-Kurosawa, Deborah J., Eaton, Lynne, Yamada, S. Diane

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel) in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal... gan Coleman, Robert L., Brady, William E., McMeekin, D. Scott, Rose, Peter G., Soper, John T., Lentz, Samuel S., Hoffman, James S., Shahin, Mark S.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Necessity of Radical Hysterectomy for Endometrial Cancer Patients with Cervical Invasion gan Lee, Taek Sang, Kim, Jae Weon, Kim, Dae Yeon, Kim, Young Tae, Lee, Ki Heon, Kim, Byoung Gie, McMeekin, D. Scott

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study gan Monk, Bradley J., Sill, Michael W., McMeekin, D. Scott, Cohn, David E., Ramondetta, Lois M., Boardman, Cecelia H., Benda, Jo, Cella, David

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Phase I Study of Concurrent Weekly Topotecan and Cisplatin Chemotherapy with Whole Pelvic Radiation Therapy in Locally Advanced Cervical Cancer: a Gynecologic Oncology Group Stud... gan Rose, Peter G., Sill, Michael W., McMeekin, D. Scott, Ahmed, Amina, Salani, Ritu, Yamada, S. Diane, Wolfson, Aaron, Fusco, Nancy, Fracasso, Paula M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A phase II evaluation of Irofulven (IND#55804, NSC#683863) as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cance... gan Schilder, Russell J., Blessing, John A., Shahin, Mark S., Miller, David S, Tewari, Krishnansu Sujata, Muller, Carolyn Y., Warshal, David, McMeekin, D. Scott, Rotmensch, Jacob

Cael y testun llawn Cael y testun llawn

Phase II trial of Cetuximab in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study gan Santin, Alessandro D., Sill, Michael W., McMeekin, D. Scott, Leitao, Mario M., Brown, Jubilee, Sutton, Gregory P., Van Le, Linda, Griffin, Patricia, Boardman, Cecelia H.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study gan Aghajanian, Carol, Sill, Michael W., Darcy, Kathleen M., Greer, Benjamin, McMeekin, D. Scott, Rose, Peter G., Rotmensch, Jacob, Barnes, Mack N., Hanjani, Parviz, Leslie, Kimberly K.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Ultra-early Predictive Assay for Treatment Failure Using Functional Magnetic Resonance Imaging and Clinical Prognostic Parameters in Cervical Cancer gan Mayr, Nina A., Yuh, William T. C., Jajoura, David, Wang, Jian Z., Lo, Simon S., Montebello, Joseph F., Porter, Kyle, Zhang, Dongqing, McMeekin, D. Scott, Buatti, John M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass gan Moore, Richard G., McMeekin, D. Scott, Brown, Amy K., DiSilvestro, Paul, Miller, M. Craig, Allard, W. Jeffrey, Gajewski, Walter, Kurman, Robert, Bast, Robert C., Skates, Steven J.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Etiologic Heterogeneity in Endometrial Cancer: Evidence from a Gynecologic Oncology Group Trial gan Brinton, Louise A., Felix, Ashley S., McMeekin, D. Scott, Creasman, William T., Sherman, Mark E., Mutch, David, Cohn, David E., Walker, Joan L., Moore, Richard G., Downs, Levi S., Soslow, Robert A., Zaino, Richard

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial gan Felix, Ashley S., Brinton, Louise A., McMeekin, D. Scott, Creasman, William T., Mutch, David, Cohn, David E., Walker, Joan L., Moore, Richard G., Downs, Levi S., Soslow, Robert A., Zaino, Richard, Sherman, Mark E.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Phase 1b Dose Escalation Study of Ipafricept (OMP-54F28) in Combination with Paclitaxel and Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian Cancer gan Moore, Kathleen N., Gunderson, Camille, Sabbatini, Paul, McMeekin, D. Scott, Mantia-Smaldone, Gina, Burger, Robert, Morgan, Mark A., Kapoun, Ann M., Brachmann, Rainer Karl, Stagg, Robert, Farooki, Azeez, O’Cearbhaill, Roisin E

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase II Trial of Trastuzumab in Women with Advanced or Recurrent, HER2-Positive Endometrial Carcinoma: a Gynecologic Oncology Group Study gan Fleming, Gini F., Sill, Michael W., Darcy, Kathleen M., McMeekin, D. Scott, Thigpen, J. Tate, Adler, Lisa M., Berek, Jonathan S., Chapman, Julia A., DiSilvestro, Paul A., Horowitz, Ira R., Fiorica, James V.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 Trial gan Felix, Ashley S, McMeekin, D Scott, Mutch, David, Walker, Joan L, Creasman, William T, Cohn, David E, Ali, Shamshad, Moore, Richard G, Downs, Levi S, Ioffe, Olga B, Park, Kay J, Sherman, Mark E, Brinton, Louise A

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Phase II Trial of Brivanib in Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study gan Powell, Matthew A., Sill, Michael W., Goodfellow, Paul J., Benbrook, Doris M., Lankes, Heather A., Leslie, Kimberly K., Jeske, Yvette, Mannel, Robert S., Spillman, Monique A, Lee, Paula S., Hoffman, James S., McMeekin, D. Scott, Pollock, Pamela M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Phase II Evaluation of Aflibercept in the Treatment of Recurrent or Persistent Endometrial Cancer: a Gynecologic Oncology Group study gan Coleman, Robert L., Sill, Michael W., Lankes, Heather A., Fader, Amanda Nickles, Finkler, Neil J., Hoffman, James S., Rose, Peter G., Sutton, Gregory P., Drescher, Charles W., McMeekin, D. Scott, Hu, Wei, Deavers, Michael, Godwin, Andrew K., Alpaugh, R. Katherine, Sood, Anil K.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer gan Randall, Marcus E., Filiaci, Virginia, McMeekin, D. Scott, von Gruenigen, Vivian, Huang, Helen, Yashar, Catheryn M., Mannel, Robert S., Kim, Jae-Weon, Salani, Ritu, DiSilvestro, Paul A., Burke, James J., Rutherford, Thomas, Spirtos, Nick M., Terada, Keith, Anderson, Penny R., Brewster, Wendy R., Small, William, Aghajanian, Carol A., Miller, David S.

Cael y testun llawn Cael y testun llawn Cael y testun llawn